Ophthalmology | Phase I Developments

Adverum Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Pharma Nanotech & Nanomedicine

Participation Not Confirmed

Request a Meeting Now

Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the An...

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Adverum Biotechnologies is conducting a phase1 study of Intravitreal gene therapy with ADVM-022 for Neovascular AMD (OPTIC Trial).

Adverum Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Pharma Nanotech & Nanomedicine

Participation Not Confirmed

Request a Meeting Now

Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outl...

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 12, 2020

Details:

OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20. IND application planned for ADVM-022 in diabetic retinopathy in 1H20.

Gemini Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Pharma Nanotech & Nanomedicine

Participation Not Confirmed

Request a Meeting Now

Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration

Lead Product(s): GEM103

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

The company looking forward to topline data from this study and the potential to initiate a Phase 2 study supported by the CLARITY natural history study data.